Starling Oncology (STLN) Operating Expenses (2020 - 2026)

For the trailing twelve months through Jun 30, 2026, Operating Expenses at Starling Oncology was $613.33 million, up 30.1% year-over-year; for FY2025, it came in at $538.81 million, up 18.8% from FY2024.

• Annual Operating Expenses has increased for five consecutive years, with a five-year compound annual growth rate of 22.5% (FY2020 to FY2025).
• In prior years, Starling Oncology's Operating Expenses was $453.53 million in FY2024 (+13.0%), $401.26 million in FY2023 (+20.0%), $334.43 million in FY2022 (+34.4%) and $248.86 million in FY2021 (+27.2%).
• The Q2 2026 figure stands as the highest quarterly Operating Expenses in data going back to Q1 2020.
• On a year-over-year basis, Operating Expenses has increased in each of the last 19 quarters, with growth averaging 20.8% over the last eight quarters.
• Over the past five years, the year-over-year growth in Operating Expenses ranged from 1.5% (Q1 2025) to 123.4% (Q4 2021).
• According to Business Quant data, Operating Expenses for the three prior quarters was $153.95 million (Q1 2026), $148.86 million (Q4 2025) and $144.62 million (Q3 2025).